Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis
Roflumilast cream potential “Best in Class” topical PDE4 inhibitorAtopic dermatitis affects approximately 19 million patients in the U.S.The Company anticipates...